Zach Shen

Zach Shen

Associate

Zach Shen is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on corporate and securities law.

Experience

Zach Shen is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on corporate and securities law.

Education

J.D., University of Southern California, Gould School of Law
M.B.A., University of Southern California, Marshall School of Business
B.A., Philosophy, Politics, and Economics, University of Pennsylvania

Admissions

State Bar of California

Credentials

Education

J.D., University of Southern California, Gould School of Law
M.B.A., University of Southern California, Marshall School of Business
B.A., Philosophy, Politics, and Economics, University of Pennsylvania

Admissions

State Bar of California

Recent Insights

Client Highlights

On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.

Learn More

Client Highlights

On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.

Learn More